Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Thyroid Neoplasms 1Skin Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lung Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Oxaliplatin 31Fluorouracil 31Leucovorin 29Irinotecan 23Cetuximab 20Bevacizumab 16Capecitabine 13Gemcitabine 11pembrolizumab 8Folfox protocol 7Cisplatin 7Carboplatin 7Paclitaxel 6Nivolumab 6Cyclophosphamide 6trifluridine tipiracil drug combination 5cediranib 5Erlotinib Hydrochloride 5adagrasib 4Ipilimumab 4IFL protocol 4Floxuridine 4Bortezomib 4veliparib 3trametinib 3sargramostim 3poly ICLC 3binimetinib 3Trifluridine 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Colonic Neoplasms × CALAA-01 × Clear all
NCT00689065 2013-11-01

Safety Study of CALAA-01 to Treat Solid Tumor Cancers

Calando Pharmaceuticals

Phase 1 Terminated
24 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Skin Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡